Bone marrow transplantation is generally available for myelofibrosis, but this treatment option is not available for many patients due to their age and physical condition.
Bone marrow transplantation is an option for myelofibrosis, but it also requires a comprehensive analysis that takes into account the patient’s age, physical condition, poor prognosis and genetic mutations. If in the low-risk group, it is generally recommended to supportive treatment, such as rucotinib oral; intermediate-risk group and high-risk group supportive treatment effect is poor, in line with the conditions of transplantation, bone marrow transplantation.
Myelofibrosis is a myeloproliferative disorder that includes primary myelofibrosis and secondary myelofibrosis. The specific cause of primary myelofibrosis is not yet clear, which may be related to the abnormal stimulation of hematopoietic stem cells; secondary myelofibrosis may be related to physical factors, chemical factors, infections, tumors and so on.
Patients with myelofibrosis are advised to consult a doctor in time and take standardized treatment under the doctor’s guidance to avoid delaying the condition.